Abstract
This review summarizes studies on humoral immune responses against tumor-associated antigens (TAAs) with a focus on antibody frequencies and the potential diagnostic, prognostic, and etiologic relevance of antibodies against TAAs. We performed a systematic literature search in Medline and identified 3,619 articles on humoral immune responses and TAAs. In 145 studies, meeting the inclusion criteria, humoral immune responses in cancer patients have been analyzed against over 100 different TAAs. The most frequently analyzed antigens were p53, MUC1, NY-ESO-1, c-myc, survivin, p62, cyclin B1, and Her2/neu. Antibodies against these TAAs were detected in 0–69% (median 14%) of analyzed tumor patients. Antibody frequencies were generally very low in healthy individuals, with the exception of few TAAs, especially MUC1. For several TAAs, including p53, Her2/neu, and NY-ESO-1, higher antibody frequencies were reported when tumors expressed the respective TAA. Antibodies against MUC1 were associated with a favorable prognosis while antibodies against p53 were associated with poor disease outcome. These data suggest different functional roles of endogenous antibodies against TAAs. Although data on prediagnostic antibody levels are scarce and antibody frequencies for most TAAs are at levels precluding use in diagnostic assays for cancer early detection, there is some promising data on achieving higher sensitivity for cancer detection using panels of TAAs.
Similar content being viewed by others
References
Kamradt T, Mitchison NA (2001) Tolerance and autoimmunity. N Engl J Med 344:655–664
Fonseca C, Dranoff G (2008) Capitalizing on the immunogenicity of dying tumor cells. Clin Cancer Res 14:1603–1608
Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2:293–299
Turk MJ, Wolchok JD, Guevara-Patino JA et al (2002) Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol Rev 188:122–135
Delves PJ, Roitt IM (2000) The immune system. First of two parts. N Engl J Med 343:37–49
Houghton AN (1994) Cancer antigens: immune recognition of self and altered self. J Exp Med 180:1–4
Jäger E, Jäger D, Knuth A (2003) Antigen-specific immunotherapy and cancer vaccines. Int J Cancer 106:817–820
Renkvist N, Castelli C, Robbins PF et al (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50:3–15
Finn OJ (2008) Cancer immunology. N Engl J Med 358:2704–2715
Rescigno M, Avogadri F, Curigliano G (2007) Challenges and prospects of immunotherapy as cancer treatment. Biochim Biophys Acta 1776:108–123
Himoto T, Kuriyama S, Zhang JY et al (2005) Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma. Int J Oncol 27:1079–1085
Zhang JY, Casiano CA, Peng XX et al (2003) Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 12:136–143
Zhang JY, Megliorino R, Peng XX et al (2007) Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol 46:107–114
Mensdorff-Pouilly S, Verstraeten AA, Kenemans P et al (2000) Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18:574–583
Croce MV, Isla-Larrain MT, Capafons A et al (2001) Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women. Breast Cancer Res Treat 69:1–11
Kurtenkov O, Klaamas K, Rittenhouse-Olson K et al (2005) IgG immune response to tumor-associated carbohydrate antigens (TF, Tn, alphaGal) in patients with breast cancer: impact of neoadjuvant chemotherapy and relation to the survival. Exp Oncol 27:136–140
Kurtenkov O, Klaamas K, Mensdorff-Pouilly S et al (2007) Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival. Acta Oncol 46:316–323
Hamanaka Y, Suehiro Y, Fukui M et al (2003) Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 103:97–100
Ralhan R, Nath N, Agarwal S et al (1998) Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Clin Cancer Res 4:2147–2152
Looi K, Megliorino R, Shi FD et al (2006) Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep 16:1105–1110
Koziol JA, Zhang JY, Casiano CA et al (2003) Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 9:5120–5126
Ralhan R, Arora S, Chattopadhyay TK et al (2000) Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int J Cancer 85:791–795
Richards ER, Devine PL, Quin RJ et al (1998) Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother 46:245–252
Graves CR, Robertson JF, Murray A et al (2005) Malignancy-induced autoimmunity to MUC1: initial antibody characterization. J Pept Res 66:357–363
Green JA, Mudenda B, Jenkins J et al (1994) Serum p53 auto-antibodies: incidence in familial breast cancer. Eur J Cancer 30A:580–584
Davidoff AM, Iglehart JD, Marks JR (1992) Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 89:3439–3442
Komiya T, Hirashima T, Takada M et al (1997) Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung. Anticancer Res 17:3721–3724
Kressner U, Glimelius B, Bergstrom R et al (1998) Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer 77:1848–1851
Hammel P, Leroy-Viard K, Chaumette MT et al (1999) Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer. Int J Cancer 81:712–718
Bourhis J, Lubin R, Roche B et al (1996) Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 88:1228–1233
Lechpammer M, Lukac J, Lechpammer S et al (2004) Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis 19:114–120
Soussi T (2000) p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60:1777–1788
Jäger E, Stockert E, Zidianakis Z et al (1999) Humoral immune responses of cancer patients against “Cancer-Testis” antigen NY-ESO-1: correlation with clinical events. Int J Cancer 84:506–510
Maio M, Coral S, Sigalotti L et al (2003) Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. J Clin Endocrinol Metab 88:748–754
Stockert E, Jäger E, Chen YT et al (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187:1349–1354
Goodell V, Waisman J, Salazar LG et al (2008) Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther 7:449–454
Karsten U, Mensdorff-Pouilly S, Goletz S (2005) What makes MUC1 a tumor antigen? Tumour Biol 26:217–220
Reuschenbach M, Waterboer T, Wallin KL et al (2008) Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers. Int J Cancer 123:2626–2631
Akcakanat A, Kanda T, Koyama Y et al (2004) NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol 54:95–100
Fossa A, Berner A, Sophie DF et al (2004) NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 59:440–447
Wadle A, Kubuschok B, Imig J et al (2006) Serological immune response to cancer testis antigens in patients with pancreatic cancer. Int J Cancer 119:117–125
Chang JT, Wong FH, Liao CT et al (2004) Enzyme immunoassay for serum autoantibody to survivin and its findings in head-and-neck cancer patients. Clin Chem 50:1261–1264
Fishman P, Merimski O, Baharav E et al (1997) Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Cancer 79:1461–1464
Disis ML, Pupa SM, Gralow JR et al (1997) High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15:3363–3367
Nakamura H, Hinoda Y, Nakagawa N et al (1998) Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J Gastroenterol 33:354–361
Traina A, Agostara B, Marasa L et al (2006) HER2/neu expression in relation to clinicopathologic features of breast cancer patients. Ann N Y Acad Sci 1089:159–167
Ferretti G, Felici A, Papaldo P et al (2007) HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 19:56–62
Nesterova M, Johnson N, Cheadle C et al (2006) Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta 1762:398–403
Kim JH, Herlyn D, Wong KK et al (2003) Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 9:4782–4791
Qin S, Qiu W, Ehrlich JR et al (2006) Development of a “reverse capture” autoantibody microarray for studies of antigen-autoantibody profiling. Proteomics 6:3199–3209
Philip R, Murthy S, Krakover J et al (2007) Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J Proteome Res 6:2509–2517
Lu H, Goodell V, Disis ML (2008) Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 7:2168
Ran Y, Hu H, Zhou Z et al (2008) Profiling tumor-associated autoantibodies for the detection of colon cancer. Clin Cancer Res 14:2696–2700
Abendstein B, Marth C, Müller-Holzner E et al (2000) Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. Cancer 88:1432–1437
Mayerhofer K, Tempfer C, Kucera E et al (1999) Humoral p53 antibody response is a prognostic parameter in ovarian cancer. Anticancer Res 19:875–878
Volkmann M, Sinn HP, Gaugel D et al (2002) Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression. Oncology 63:297–305
Tang R, Ko MC, Wang JY et al (2001) Humoral response to p53 in human colorectal tumors: a prospective study of 1, 209 patients. Int J Cancer 94:859–863
Lai CL, Tsai CM, Tsai TT et al (1998) Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Clin Cancer Res 4:3025–3030
Qiu LL, Hua PY, Ye LL et al (2007) The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China. Cancer Detect Prev 31:45–49
Sangrajrang S, Arpornwirat W, Cheirsilpa A et al (2003) Serum p53 antibodies in correlation to other biological parameters of breast cancer. Cancer Detect Prev 27:182–186
Jezersek B, Rudolf Z, Novakovic S (2001) The circulating auto-antibodies to p53 protein in the follow-up of lymphoma patients. Oncol Rep 8:77–81
Shimada H, Takeda A, Arima M et al (2000) Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 89:1677–1683
Vogl FD, Stickeler E, Weyermann M et al (1999) p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells. Oncology 57:324–329
Scott N, Sagar P, Stewart J et al (1991) p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 63:317–319
Qin Z, Richter G, Schüler T et al (1998) B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 4:627–630
Gumus E, Erdamar S, Demirel G et al (2004) Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. Int J Urol 11:1070–1077
Manson LA (1991) Does antibody-dependent epitope masking permit progressive tumour growth in the face of cell-mediated cytotoxicity? Immunol Today 12:352–355
Tan TT, Coussens LM (2007) Humoral immunity, inflammation and cancer. Curr Opin Immunol 19:209–216
Imai H, Ochs RL, Kiyosawa K et al (1992) Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol 140:859–870
Trivers GE, Cawley HL, DeBenedetti VM et al (1995) Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst 87:1400–1407
Lubin R, Schlichtholz B, Teillaud JL et al (1995) p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res 1:1463–1469
Schlichtholz B, Legros Y, Gillet D et al (1992) The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52:6380–6384
Lubin R, Zalcman G, Bouchet L et al (1995) Serum p53 antibodies as early markers of lung cancer. Nat Med 1:701–702
Schlichtholz B, Tredaniel J, Lubin R et al (1994) Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 69:809–816
Angelopoulou K, Diamandis EP, Sutherland DJ et al (1994) Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58:480–487
Hammel P, Boissier B, Chaumette MT et al (1997) Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 40:356–361
Korangy F, Ormandy LA, Bleck JS et al (2004) Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 10:4332–4341
Yonezawa S, Goto M, Yamada N et al (2008) Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics 8:3329–3341
Parmigiani RB, Bettoni F, Grosso DM et al (2008) Antibodies against the cancer-testis antigen CTSP-1 are frequently found in prostate cancer patients and are an independent prognostic factor for biochemical-recurrence. Int J Cancer 122:2385–2390
Bachelot T, Ratel D, Menetrier-Caux C et al (2006) Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome. Br J Cancer 94:1066–1070
Hirasawa Y, Kohno N, Yokoyama A et al (2000) Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 161:589–594
Shimada H, Kuboshima M, Shiratori T et al (2007) Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol 30:97–103
Boon T, van der BP (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725–729
Finn OJ (2007) Human tumor immunology at the molecular divide. J Immunol 178:2615–2616
Wesseling J, van der Valk SW, Hilkens J (1996) A mechanism for inhibition of E-cadherin-mediated cell–cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 7:565–577
Agrawal B, Krantz MJ, Reddish MA et al (1998) Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 4:43–49
Gourevitch MM, Mensdorff-Pouilly S, Litvinov SV et al (1995) Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br J Cancer 72:934–938
Cramer DW, Titus-Ernstoff L, McKolanis JR et al (2005) Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 14:1125–1131
Menard S, Casalini P, Campiglio M et al (2004) Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 61:2965–2978
Jager D, Knuth A (2005) Antibodies and vaccines—hope or illusion? Breast 14:631–635
Montgomery RB, Makary E, Schiffman K et al (2005) Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res 65:650–656
Disis ML, Schiffman K (2001) Cancer vaccines targeting the HER2/neu oncogenic protein. Semin Oncol 28:12–20
Chapman CJ, Murray A, McElveen JE et al (2008) Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 63:228–233
Yamamoto A, Shimizu E, Ogura T et al (1996) Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients. Int J Cancer 69:283–289
Chen Y, Lin P, Qiu S et al (2007) Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection. Int J Oncol 30:1137–1144
Ersvaer E, Zhang JY, McCormack E et al (2007) Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. Eur J Haematol 79:210–225
Shi FD, Zhang JY, Liu D et al (2005) Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate 63:252–258
Disis ML, Calenoff E, McLaughlin G et al (1994) Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54:16–20
McNeel DG, Nguyen LD, Storer BE et al (2000) Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urol 164:1825–1829
Chapman C, Murray A, Chakrabarti J et al (2007) Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 18:868–873
Snijdewint FG, Mensdorff-Pouilly S, Karuntu-Wanamarta AH et al (1999) Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls. Cancer Immunol Immunother 48:47–55
Türeci O, Mack U, Luxemburger U et al (2006) Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett 236:64–71
Nakamura S, Nouso K, Noguchi Y et al (2006) Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. J Gastroenterol Hepatol 21:1281–1285
Hogdall EV, Hogdall CK, Blaakaer J et al (2002) P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis. APMIS 110:545–553
Kaur J, Srivastava A, Ralhan R (1997) Serum p53 antibodies in patients with oral lesions: correlation with p53/HSP70 complexes. Int J Cancer 74:609–613
Castelli M, Cianfriglia F, Manieri A et al (2001) Anti-p53 and anti-heat shock proteins antibodies in patients with malignant or pre-malignant lesions of the oral cavity. Anticancer Res 21:753–758
Volkmann M, Muller M, Hofmann WJ et al (1993) The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status. Hepatology 18:559–565
Coomber D, Hawkins NJ, Clark M et al (1996) Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer. J Cancer Res Clin Oncol 122:757–762
Lubin R, Schlichtholz B, Bengoufa D et al (1993) Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 53:5872–5876
Angelopoulou K, Stratis M, Diamandis EP (1997) Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer 70:46–51
Creaney J, McLaren BM, Stevenson S et al (2001) p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression. Br J Cancer 84:52–56
Labrecque S, Naor N, Thomson D et al (1993) Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 53:3468
Selter H, Schmidt G, Villena-Heinsen C et al (1999) Humoral immune response to p21WAF1/CIP1 in tumor patients, non-tumorous patients and healthy blood donors. Cancer Lett 137:151–157
Zhang JY, Zhu W, Imai H et al (2001) De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin Exp Immunol 125:3–9
Zhang JY, Chan EK, Peng XX et al (2001) Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol 100:149–156
Yagihashi A, Asanuma K, Kobayashi D et al (2005) Detection of autoantibodies to livin and survivin in Sera from lung cancer patients. Lung Cancer 48:217–221
Yagihashi A, Ohmura T, Asanuma K et al (2005) Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin Chim Acta 362:125–130
Yagihashi A, Asanuma K, Kobayashi D et al (2005) Autoantibodies to survivin in patients with chronic hepatitis and hepatocellular carcinoma. Autoimmunity 38:445–448
Anderson KS, Ramachandran N, Wong J et al (2008) Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res 7:1490–1499
Soling A, Plugge EM, Schmitz M et al (2007) Autoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors. Int J Oncol 30:123–128
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Reuschenbach, M., von Knebel Doeberitz, M. & Wentzensen, N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 58, 1535–1544 (2009). https://doi.org/10.1007/s00262-009-0733-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-009-0733-4